China's Peijia Medical H1 revenue jumps on transcatheter valve therapeutics growth

Peijia Medical

24/08/2026 13:14

Overview
China medical device maker's interim revenue grew 20.1% yr/yr, reaching RMB424.5 mln
Company achieved first-ever profit before tax, driven by strong TAVR business growth
Net loss narrowed 87.4% yr/yr, with improved cash generation and operating leverage

Outlook
Company expresses confidence in second half of 2026 and long-term future

Result Drivers
TAVR BUSINESS EXPANSION - Revenue growth was led by transcatheter valve therapeutics, with TaurusTrio system launch and rapid adoption for aortic regurgitation treatment
NEUROINTERVENTIONAL PROFIT GROWTH - Neurointerventional business delivered strong profit growth, driven by portfolio expansion and strategic partnerships
OPERATING LEVERAGE - Improved operational efficiency and reduced expenses supported profitability as commercial platform scaled

Company press release: ID:nPn9ssXDwa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 424.5 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Peijia Medical Ltd is HK$9.60, about 80.5% above its August 24 closing price of HK$5.32
The stock recently traded at 44 times the next 12-month earnings vs. a P/E of 93 three months ago

Reuters Recommended Reads
Aug 24 - China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growth
Aug 24 - Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Aug 21 - China's Haohai Biological H1 revenue falls, partly hurt by end of Brighten Optix distribution

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)